Mostrar el registro sencillo

dc.contributor.authorPulito Cueto, Verónica
dc.contributor.authorRemuzgo Martínez, Sara
dc.contributor.authorGenre, Fernanda
dc.contributor.authorAtienza Mateo, Belén  
dc.contributor.authorMora Cuesta, Víctor Manuel
dc.contributor.authorIturbe Fernández, David 
dc.contributor.authorLera-Gómez, Leticia
dc.contributor.authorPérez Fernández, Raquel
dc.contributor.authorPrieto Peña, Diana 
dc.contributor.authorPortilla González, Virginia
dc.contributor.authorBlanco Alonso, Ricardo 
dc.contributor.authorCorrales Martínez, Alfonso
dc.contributor.authorGualillo, Oreste
dc.contributor.authorCifrián Martínez, José Manuel 
dc.contributor.authorLópez Mejías, Raquel
dc.contributor.authorGonzález-Gay Mantecón, Miguel Ángel 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2022-03-24T16:10:55Z
dc.date.available2022-03-24T16:10:55Z
dc.date.issued2021
dc.identifier.issn2227-9059
dc.identifier.urihttp://hdl.handle.net/10902/24350
dc.description.abstractEndothelial progenitor cells (EPC), which are key effectors in the physiologic vascular network, have been described as relevant players in autoimmune diseases. We previously showed that EPC frequency may help to identify the presence of interstitial lung disease (ILD) in rheumatoid arthritis patients. Given that ILD constitutes the main cause of mortality in systemic sclerosis (SSc) patients, we aimed to determine the EPC contribution to the pathogenic processes of vasculopathy and lung fibrosis in SSc-ILD+. EPC quantification was performed by flow cytometry on blood from 83 individuals: 21 SSc-ILD+ patients and subjects from comparative groups (20 SSc-ILD- and 21 idiopathic pulmonary fibrosis (IPF) patients and 21 healthy controls (HC)). EPC were considered as CD34+, CD45low, CD309+, and CD133+. A significant increase in EPC frequency was found in SSc-ILD+ patients when compared to HC (p < 0.001). SSc-ILD+ patients exhibited a higher EPC frequency than SSc-ILD- patients (p = 0.012), whereas it was markedly reduced compared to IPF patients (p < 0.001). EPC frequency was higher in males (p = 0.04) and negatively correlated to SSc duration (p = 0.04) in SSc-ILD+ patients. Our results indicate a role of EPC in the processes of vasculopathy and lung fibrosis in SSc-ILD+. EPC frequency may be considered as a biomarker of ILD in SSc patients.es_ES
dc.description.sponsorshipV.P.-C. is supported by a pre-doctoral grant from IDIVAL [PREVAL 18/01]. S.R.-M. is supported by funds from the RETICS Program [RD16/0012/0009, Instituto de Salud Carlos III (ISCIII), co-funded by the European Regional Development Fund (ERDF)]. B.A.-M. is a recipient of a ‘López Albo’ Post-Residency Programme funded by Servicio Cántabro de Salud. L.L.-G. is supported by funds from INNVAL20/06 (IDIVAL). R.P.-F. is supported by funds from the START project [FOREUM18/34]. O.G. is staff personnel of Xunta de Galicia (Servizo Galego de Saude (SERGAS) through a research-staff stabilization contract (ISCIII/SERGAS), and his work is funded by ISCIII and the ERDF [grants RD16/0012/0014 (RIER) and PI17/00409]. He is a beneficiary of project funds from the Research Executive Agency (REA) of the European Union in the framework of MSCA-RISE Action of the H2020 Programme, project 734899—Olive-Net. R.L.-M. is a recipient of a Miguel Servet type I fellowship [ISCIII, co-funded by the European Social Fund, ‘Investing in your future’, CP16/00033].es_ES
dc.format.extent9 p.es_ES
dc.language.isoenges_ES
dc.publisherMDPI AGes_ES
dc.rights©2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceBiomedicines . 2021 Jul 20;9(7):847es_ES
dc.subject.otherEndothelial progenitor cellses_ES
dc.subject.otherSystemic sclerosises_ES
dc.subject.otherInterstitial lung diseasees_ES
dc.subject.otherBiomarkeres_ES
dc.titleEndothelial Progenitor Cells: Relevant Players in the Vasculopathy and Lung Fibrosis Associated with the Presence of Interstitial Lung Disease in Systemic Sclerosis Patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.3390/biomedicines9070847es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3390/biomedicines9070847
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

©2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.Excepto si se señala otra cosa, la licencia del ítem se describe como ©2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.